Gast ::
| Hauptseite > Publikationsdatenbank > 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for PET imaging of the A1 adenosine receptor > print |
| Hauptseite > Publikationsdatenbank > 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for PET imaging of the A1 adenosine receptor > print |
| 001 | 1027692 | ||
| 005 | 20240624202013.0 | ||
| 024 | 7 | _ | |a 10.1016/S0969-8051(22)00096-8 |2 doi |
| 024 | 7 | _ | |a 0969-8051 |2 ISSN |
| 024 | 7 | _ | |a 1872-9614 |2 ISSN |
| 037 | _ | _ | |a FZJ-2024-04004 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 570 |
| 100 | 1 | _ | |a Holschbach, Marcus |0 P:(DE-Juel1)131824 |b 0 |u fzj |
| 111 | 2 | _ | |a 24th International Symposium on Radiopharmaceutical Sciences |g ISRS2022 |c Nantes |d 2022-05-29 - 2022-06-03 |w France |
| 245 | _ | _ | |a 8-Bicycloalkyl-CPFPX derivatives as potent and selective tools for PET imaging of the A1 adenosine receptor |
| 260 | _ | _ | |c 2022 |
| 336 | 7 | _ | |a Conference Paper |0 33 |2 EndNote |
| 336 | 7 | _ | |a Other |2 DataCite |
| 336 | 7 | _ | |a INPROCEEDINGS |2 BibTeX |
| 336 | 7 | _ | |a conferenceObject |2 DRIVER |
| 336 | 7 | _ | |a LECTURE_SPEECH |2 ORCID |
| 336 | 7 | _ | |a Conference Presentation |b conf |m conf |0 PUB:(DE-HGF)6 |s 1719202479_3990 |2 PUB:(DE-HGF) |x After Call |
| 520 | _ | _ | |a Objectives: The first successful in-house development [1] ofa radiofluorinated A 1 adenosine receptor (A1AR) antagonist withnanomolar affinity for the bovine A 1 AR for in vivo PET studies was8-cyclopentyl-3-(3-[ 18 F]Fluoropropyl)-1-propyl-xanthine, [ 18 F]CPFPX. Although this ligand proved to be useful in vivo in rodents,already first preclinical studies revealed possible limitations for PETimaging. At the beginning our efforts aimed at synthesizing metabol-ically stabilized CPFPX derivatives, but the recently published findingby Schneider et al. [2] that affinity is the key pharmacokinetic deter-minant of radiolabeled xanthines in the brain prompted us to focusour efforts on the synthesis of A1AR ligands with high affinity.Methods: In search of CPFPX-like A1AR ligands with higher targetaffinity, we decided to replace the cyclopentyl residue in the 8-posi-tion of the xanthine backbone with sterically more demanding nor-bornyl residues [3]. The target xanthines and the radiofluorinationprecursors (sulfonates) were synthesized through multistep syn-theses by a modified Traube protocol [4]. Binding experiments wereperformed with membranes from CHO K1 cells stably transfectedwith either the human A1 or A2AAR. Nucleophilic radiofluorinationon the n.c.a level used the classical Kryptofix™ 2.2.2/K 2 CO 3 method.For in vitro autoradiography, frozen horizontal sections (20 μm) of ratbrains were used.Results: From a series of newly synthesized compounds 1-NBXhas emerged as the most potent and selective candidate (Figure 1).The norbornyl group has two surfaces, one being essentially a cyclo-pentyl ring backed by a two-carbon bridge and the other being acyclohexyl ring backed by a one-carbon bridge. The greater potencyof 1-NBX relative to the 2- and 7-norbornyl isomers probably occursbecause 1-NBX binds to the receptor with its cyclopentyl surfacefacing the receptor, whereas the 2- and 7-isomers are forced to bindwith the less favorable cyclohexyl ring facing the receptor.Cyclopentane exists mainly in an “envelope” conformation, in whichfour of the carbons form the corners of a flat envelope, and the fifthcarbon represents the apex of a triangular flap, which projects at anangle of about 120° from the body of the envelope [5, 6]. Althoughany of the carbons can take the out-of-plane position in cyclopen-tane, in norbornane the bridging carbon is locked in this position.The greater affinity of 1-NBX compared to that of CPFPX is mostlikely due to the former being locked in the optimal conformation. Asexpected from earlier studies, 1-propyl and 3-fluoropropylsubstitution at both 1- and 3-positions of the xanthine scaffold wasoptimum to potent and selective A1AR antagonism.#Conclusions: [ 18 F]1-NBX seems to be a promising A1AR antagonisttracer suitable for PET. Future preclinical studies will reveal weather1 NBX will have the potential to serve as a substitute for [ 18 F]CPFPX.References:[1] Holschbach et al., J Med Chem. 2002, 45(23), 5150-5156.[2] Schneider et al., Nucl Med Biol. 2020, 82-83, 1-8.[3] Shimada et al., J Med Chem. 1992, 35, 924-930.[4] Holschbach et al., Org Lett. 2009, 11, 4266-4269.[5] Dragojlovic V., ChemTexts 2015, 1, 14.[6] Trivedi et al., J Med Chem 1989, 32, 8-11 |
| 536 | _ | _ | |a 5253 - Neuroimaging (POF4-525) |0 G:(DE-HGF)POF4-5253 |c POF4-525 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, Journals: juser.fz-juelich.de |
| 700 | 1 | _ | |a Humpert, Swen |0 P:(DE-Juel1)132740 |b 1 |e Corresponding author |u fzj |
| 700 | 1 | _ | |a Schneider, Daniela |0 P:(DE-Juel1)156407 |b 2 |u fzj |
| 700 | 1 | _ | |a Schulze, Annette |0 P:(DE-Juel1)131847 |b 3 |u fzj |
| 700 | 1 | _ | |a Bier, Dirk |0 P:(DE-Juel1)131810 |b 4 |u fzj |
| 700 | 1 | _ | |a Neumaier, Bernd |0 P:(DE-Juel1)166419 |b 5 |u fzj |
| 773 | _ | _ | |a 10.1016/S0969-8051(22)00096-8 |0 PERI:(DE-600)1498538-X |y 2022 |g Vol. 108-109, p. S26 - S27 |x 0969-8051 |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027692/files/1-s2.0-S0969805122000968-main.pdf |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027692/files/1-s2.0-S0969805122000968-main.gif?subformat=icon |x icon |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027692/files/1-s2.0-S0969805122000968-main.jpg?subformat=icon-1440 |x icon-1440 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027692/files/1-s2.0-S0969805122000968-main.jpg?subformat=icon-180 |x icon-180 |y Restricted |
| 856 | 4 | _ | |u https://juser.fz-juelich.de/record/1027692/files/1-s2.0-S0969805122000968-main.jpg?subformat=icon-640 |x icon-640 |y Restricted |
| 909 | C | O | |o oai:juser.fz-juelich.de:1027692 |p VDB |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 0 |6 P:(DE-Juel1)131824 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 1 |6 P:(DE-Juel1)132740 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 2 |6 P:(DE-Juel1)156407 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 3 |6 P:(DE-Juel1)131847 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 4 |6 P:(DE-Juel1)131810 |
| 910 | 1 | _ | |a Forschungszentrum Jülich |0 I:(DE-588b)5008462-8 |k FZJ |b 5 |6 P:(DE-Juel1)166419 |
| 913 | 1 | _ | |a DE-HGF |b Key Technologies |l Natural, Artificial and Cognitive Information Processing |1 G:(DE-HGF)POF4-520 |0 G:(DE-HGF)POF4-525 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-500 |4 G:(DE-HGF)POF |v Decoding Brain Organization and Dysfunction |9 G:(DE-HGF)POF4-5253 |x 0 |
| 915 | _ | _ | |a Nationallizenz |0 StatID:(DE-HGF)0420 |2 StatID |d 2023-08-22 |w ger |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NUCL MED BIOL : 2022 |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |d 2023-08-22 |
| 915 | _ | _ | |a No Peer Review |0 StatID:(DE-HGF)0020 |2 StatID |b ASC |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |d 2023-08-22 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1190 |2 StatID |b Biological Abstracts |d 2023-08-22 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2023-08-22 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2023-08-22 |
| 920 | _ | _ | |l yes |
| 920 | 1 | _ | |0 I:(DE-Juel1)INM-5-20090406 |k INM-5 |l Nuklearchemie |x 0 |
| 980 | _ | _ | |a conf |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-Juel1)INM-5-20090406 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|